Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Summary

This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose modifications and avoid neutropenic fever (fever in the setting of low neutrophils) for people with Duffy null phenotype receiving treatment for multiple myeloma or triple negative breast cancer.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Multiple Myeloma
• Triple Negative Breast Cancer
• Duffy Blood Group, Chemokine Receptor Gene Mutation
• Duffy Blood Group, Chemokine Receptor Gene C.-67T>C

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Andrew Hantel, MD

Last updated on ClinicalTrials.gov

August 17, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites